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Docetaxel versus Paclitaxel Combined with 5-FU and
Leucovorin in Advanced Gastric Cancer: Combined
Analysis of Two Phase II Trials 
I n t r o d u c t i o n
Stomach cancer shows a moderate degree of the sensitivity to anti-
cancer drugs. According to randomized clinical trials which were
conducted in patients with advanced stomach cancer, a combined
anti-cancer treatment significantly had a prolonged survival period
and an improvement of the quality of life as compared with the best
supportive care group. To date, many treatment regimens have been
developed to fulfill these objectives (1,2). Despite a great number of
Phase III clinical trials, however, there are no established answers to
the best combination of various anti-cancer drugs. To date, depending
on the results of clinical trials and the preferences of researchers, the
combination treatments based on 5-FU, anthracycline and cisplatin
have been proposed as a standard treatment modality. But their effects
and the degree of prolonging the survival period are not satisfactory
yet. Considering the systemic status and a short survival period of
patients with stomach cancer, the toxicity accompanied by the treat-
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Purpose
This is an ad hoc analysis of two phase II studies which compared the efficacy and safety of
two taxanes (paclitaxel and docetaxel) combined with 5-fluorouracil (5-FU) and leucovorin
(LV) in advanced gastric cancer. 
Materials and Methods
Patients with advanced gastric adenocarcinoma who were untreated or had only received
first-line chemotherapy, were treated with either paclitaxel (PFL; 175 mg/m2) or docetaxel
(DFL; 75 mg/m2) on day 1, followed by a bolus of LV (20 mg/m2 days 1�3) and a 24-hour
infusion of 5-FU (1,000 mg/m2 days 1�3) every 3 weeks. The primary endpoint was overall
response rate (ORR) and the secondary endpoint included survival and toxicity.   
Results
Sixty-six patients received DFL (first-line [n=38]; and second-line [n=28]) and 60 patients
received PFL (first-line [n=37]; and second-line [n=23]). The ORRs were not significantly
different between the 2 groups (DFL, 26%; PFL, 38%). With a median follow-up of 9.5 months,
the progression free survival was 5.2 months (95% confidence interval [CI], 4.2�6.5 months)
for DFL and 3.3 months (95% CI, 1.3�5.5 months) for PFL (p=0.17). The overall survival was
also comparable between the patients who received DFL and PFL (10.0 months [95% CI, 7.2
�12.5 months] and 13.9 months [95% CI, 10.9�19.2 months], respectively; p=0.37). The most
frequent grade 3�4 adverse event was neutropenia (DFL, 71%; PFL, 62%). DFL and PFL had
different non-hematologic toxicities; specifically, grade ≥3 mucositis (5%) and diarrhea (3%)
were common in DFL, while nausea/vomiting (15%) and peripheral neuropathy (5%) were
common in PFL. 
Conclusion
Thus, the two taxanes had similar efficacy in the treatment of advanced gastric cancer, but
different toxicity profiles. Prospective comparative studies are required to further clarify the
role of taxanes in the treatment of advanced gastric cancer. 
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ment occurs to a not negligible extent. This impedes the long-term
treatment (3). Therefore, the development of anti-cancer treatments by
which the toxicity can be lowered and the quality of life can be
improved has been continually made (1). Such anti-cancer drugs that
have recently been developed to improve the previous ones including
oral 5-FU agents, oxaliplatin or irinotecan or to have new target have
been reported to be efficacious and safe as compared with the
previous ones. According to this, these drugs have been tested on
clinical trials which are conducted in patients with stomach cancer.
Of these, taxane is a remarkable drug in the sense of new target in
particular. Two representative taxane drugs include Docetaxel and
paclitaxel, whose single use has been reported to commonly have a
response rate of 17�25% in patients with progressive stomach
cancer. Of these, the efficacy and safety of docetaxel have been
demonstrated on randomized clinical trials about a combination
therapy with anti-cancer drugs since the early stage. Through V325
study, a Phase III trial, a combination treatment of cisplatin +5-FU
(CF) with docetaxel (DCF) showed that the survival period and
quality of life were significantly improved. The occurrence of the
toxicity of Grade 3�4 in severity proposed that the treatment dose
and schedule should be re-considered to accept DCF as a standard
treatment modality for cases of stomach cancer (5,6). For instance,
Thus-Patience et al. proposed that a single use of DF except for
cisplatin had an equivalent profile of the efficacy to epirubicin +
cisplatin +5-FU (ECF) or DCF (2). According to various types of
Phase II studies, a combination treatment with Paclitaxel produced a
response rate of 32�66% and a survival period of 6�12 months (3-
5). To date, however, almost no randomized clinical trials have been
attempted to compare the efficacy of these regimen. These taxanes
have a similar mode of action, and they also share the similar
pharmacokinetic/pharmacodynamic characteristics. It has been
proposed, however, that there are significant differences in the binding
sites for tubulin, the degree of affinity, toxicity and the expression of
cross-reactivity between the two drugs. In recent years, genomic
studies have also shown that there is a difference between the two
drugs based on the reports that the gene groups are different in
association with the sensitivity of two drugs (6). However, clinical
trials have been attempted to directly compare the efficacy and safety
of twp drugs in a very limited scope. It is assumed that these studies
can propose the baseline data for selecting the effective treatment
drugs and exploring the prognostic indicators associated with the
safety in patients. Given this background, the current paper re-
analyzed the treatment outcomes of prospective anti-cancer therapy
based on decetaxel or paclitaxel during the similar period in a similar
group of patients in a single-institution setting (7,8).
M a t e r i a l s  a n d  M e t h o d s
1 Patient eligibility
Inclusion criteria for the current study are as follows: (1) A
histologically/cytologically proven adenocarcinoma, (2) Metastatic or
surgically-unresectable recurrent stomach cancer, (3) A lack of the
previous history of palliative treatment (the adjuvant treatment
following the radical surgery which was completed six months before
is allowed) and patient who underwent the primary anti-cancer
treatments for palliative purposes, (4) Age of 18 years or older, (5)
Measurable or assessable lesions, (6) A performance of the
maintenance of daily lives with an Eastern Cooperative Oncology
Group (ECOG) of 0�2, (7) Patients whose hematologic, renal and
hepatic profiles were sufficient (hemoglobin ≥9.0 g/dL, WBC ≥
4,000/μL, neutrophils ≥2,000/μL, platelets≥100×103/μL, total
bilirubin: ≤1.25×the upper limit of normal value (hepatic metastasis:
≤2.0×the upper limit of normal value), creatinine: ≤1.5×the upper
limit of normal value, creatinine clearance ≥60 mL/min, AST/ALT:
≤3.0×the upper limit of normal value (hepatic metastasis: ≤5.0×
the upper limit of normal value), alkaline phosphatase (ALP): ≤3.0×
the upper limit of normal value (bone metastasis: ≤5.0×the upper
limit of normal value).
In the current study, however, the following cases were all
excluded: (1) Patients with duplicate cancer, (2) Patients with
peripheral neuropathy of ＞Grade 2 based on National Cancer
Institute common toxicity criteria (NCI-CTC), (3) Patients with CNS
metastasis, (4) Patients with uncontrolled chronic diseases.
Each treatment regimen was progressed following a receipt of
written informed consent from patients prior to the study conduct.
2 Treatment plan
On day 1, patients were intravenously given docetaxel 75 mg/m2
for an hour (DFL group) or paclitaxel 175 mg/m2 for three hours (PFL
group). Following the completion of an intravenous infusion of
Taxane, leucovorin 20 mg/m2 was intravenously administered within
two hours. Then, 5-FU 1,000 mg/m2 was continually infused via an
intravenous route (the overall dose of 5-FU: 3,000 mg/m2). Treat-
ments were repeated every third week. In both groups, the pre-treat-
ments for taxanes were performed with such traditional drugs as
dexamethasone, H2 blocker and diphenhydramine. 
In cases in which the hematologic or non-hematologic toxicity of
＞Grade 3 occurred, until a recovery was achieved to neutrophil
counts ≥1,500/μL, platelet counts ≥100,000/μL or the severity of
non-hematologic roxicity was lowered to Grade 1, an assessment was
performed at a 1-week interval. Then, the anti-cancer treatment was
delayed. For the next-cycle treatments, the dose of 5-FU and taxane
was decreased by 20% each. In the Docetaxel treatment group,
considering a higher incidence of the hematologic toxicity which has
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already been known, the preventive use of granulocyte colony-
stimulating factor (G-CSF) was performed for five days after four
days following the initiation of anti-cancer treatments. In the paclitaxel
group, the preventive use of G-CSF was not considered. Only in cases
in which the neutropenia of ＞Grade 4 occurred, based on the
judgement of physicians, it was administered for the therapeutic
purposes. In cases in which the administration of drugs was delayed
during a more than 4-week period due to the drug-related toxicities or
those in which the dose reduction by more than 40% was necessary
because of the plan of dose lowering, the corresponding patients were
dropped out of the current trial. The anti-cancer treatment was
persisted up to 12 cycles unless there were disease progression,
uncontrolled toxicity and a withdraw of written informed consent.
Thereafter, at a 3-month interval, the disease progression and patient
survival were followed up.
3 Patient evaluation
In all the patients, as the baseline assessment prior to the treatment,
physical examination, complete blood count (CBC), serum
chemistries, urine analysis and EKG were performed. A radiographic
assessment of the tumor was also performed within four weeks prior
to the treatment. During the treatment period, patients underwent CBC
on a weekly basis. Physical examination, the status of the performance
of daily lives and serum chemistries were performed every cycle. An
imaging study was performed every second cycle (six weeks). An
endoscopy was performed to confirm a complete remission.
In our patients, the treatment response was assessed according to
guidelines specified on Response Evaluation Criteria in Solid Tumors
(RECIST) Committee. Measurable lesions were defined as those
whose longest diameter exceeded 10 mm on spiral CT scans. In cases
in which the findings of over partial response were observed on an
assessment of the treatment response during the treatment, lesions
were re-confirmed following two cycles. Cases in which the clinical
deterioration was observed both clinically and radiologically even
prior to the completion of the first 2-cycle treatment or those in which
the radiologic tumor evaluation was performed more than once
following the completion of 2-cycle treatment were all considered to
have a possibility of performing an assessment of the tumor response.
A progression Free Survival (PFS) was defined as disease progression
since the date of treatment initiation, death occurrence with no respect
to the cause or the development of secondary cancer. The overall
survival (OS) was defined as the period ranging from the date of
treatment initiation to that of patients’ death. The time to response was
defined as the period ranging from the date of treatment initiation to
that when a remission (partial or complete) was first achieved. A
response duration was defined as the period ranging from the date
when a remission was first noted on an assessment of the treatment
response to that when the recurrence or disease progression were
confirmed. Drug toxicity was evaluated based on the NCI-CTC
(version 3.0), for which the date of toxicity onset, that of completion
and a causal relationship with the drugs were specified.
4 Statistical consideration
The response rate was analyzed based on intent-to-treat analysis
which was performed in all the patients who underwent treatment
following the registration with the clinical trial and per protocol
analysis in those who underwent tumor evaluation at least once. The
survival period and toxicity were analyzed in all the patients who
received the anti-cancer treatment at least once. The current study was
ad hoc retrospective analysis following the prospective one. A com-
parison of the clinical characteristics between the two groups was
made using chi-square test. A comparison of the overall response rate
was made using t-test. Besides, a comparison of the variables
associated with time was made using Log-rank test based on Kaplan-
Meier method. 
R e s u l t s
1 Patient characteristics
During a period ranging from October of 2001 to April of 2005, a
total of 126 patients (DFL=66, PFL=60) were enrolled in the current
study. In the DFL group, seven patients withdrew a written informed
consent before completing two cycles. These patients were excluded
from an assessment of the tumor response. In the PFL group, four
patients were ruled out for same reasons. Beside, all the patients in the
DFL group had measurable lesions in 59 patients excluding seven
mentioned above, an analysis of the response rate and survival could
be performed. In the PFL group, ten patients had measurablbe, non-
lesional, assessable areas. These patients were excluded from an
analysis of the response rate, but were included in an analysis of the
survival. A comparison of the baseline clinical characteristics was
made between the treatment groups, whose results were represented
in Table 1. For the primary treatment, the current drugs were
administered to 38 patients (58%) of the DFL group and 37 patients
(62%) of the PFL group (p=0.640). Besides, there were also no
significant differences in other clinical characteristics between the two
groups (Table 1). Major organs of metastasis include intrabdominal
lymph node, liver and ovary. The proportion of patients who were
suspected to have peritoneal dissemination on CT scans was 27% in
the DFL group and 28% in the PFL group.
2 Treatment and dose intensity
The administration was done at a total of 260 cycles (median 4:
range 1�10) in the DFL group and 280 cycles (median 4: range 1�
12) in the PFL group. These results showed that there was no signi-
ficant difference in the cycle of anti-cancer treatment between the two
groups (Table 2). In the DFL group, however, the cycles at which the
Hong Jae Chon, et al_Taxanes in Gastric Cancer
VOLUME 41  NUMBER 4  DECEMBER  2009  199
treatment was delayed were 90 (35%) and this was significantly higher
than 50 (18%) seen in the PFL group (p=0.02). Causes of the delayed
treatment include the hematologic toxicity (79%), which was the most
prevalent one, non-hematologic toxicity (13%) and patients’ own will
(7%). The median value of the dose intensity of Docetaxel was 21
mg/m2/week (range 13�25 mg/m2/week). The dose intensity of
paclitaxel was 53 mg/m2/week (range 37�58 mg/m2/week). The relative
dose intensity was 0.86 and 0.91 in the corresponding order, which was
significantly lower in the DFL group (p=0.02). The dose intensity of 5-
FU was 857 mg/m2/week (range 545�1,000 mg/m2/week) and 913
mg/m2/week (range 640�1,000 mg/m2/week) in the corresponding
order, which was significantly lower in the DFL group (p=0.03). 
DFL* PFL�
Enrolled patients
66 60 p-value
Sex (%) 0.55
Male 43 (65) 36 (60)
Female 23 (35) 24 (40)
Age : median (range) 53 (29�75) 52 (24� 69) 0.68
ECOG� 0.07  
0�1 38 (57.6) 27 (45.0 )
2 28 (42.4) 33 (55.0 )
Histology 0.36
Well & moderately differentiated 16 (24.2) 11 (18.3 )
Poorly differentiated  36 (54.5) 30 (50.0 )
Signet ring cell carcinoma 12 (18.2) 13 (21.7 )
Others 2 (3.0) 6 (10.0)
Prior operation 0.45
Gastrectomy 33 (50.0) 34 (56.7)
Non Gastrectomy 33 (50.0) 26 (43.3)
Chemotherapy 0.64
1st line chemotherapy 38 (57.6) 37 (61.7)
2nd line chemotherapy 28 (42.4) 23 (38.3)
Median cycles of previous chemotherapy 7 (1�13) 6 (1�12) 0.71  
Median RD§of previous chemotherapy 0 .94 (0.85�1.00) 0.89 (0.75�1.00) 0.22
Number of metastatic lesion 0.13
1 15 (22.7) 20 (33.3)
2 35 (53.0) 26 (43.3)
≥3 16 (24.2) 14 (23.4)
Site of metastasis 0.29
Abdominal lymph node 47 (51) 33 (49)
Liver 25 (27) 12 (18)
Intra abdominal mass 4 (4) 4 (6)
Others 16 (18) 19 (28)
Table 1. Patient characteristics
*docetaxel, 5-fluorouracil, and leucovorin, �paclitaxel, 5-fluorouracil, and leucovorin,  �eastern cooperative oncology group, §relative dose intensity.
Treatment group DFL* (n=66) PFL� (n=60) p-value
Treatment cycle Median (range) 4 (1�10) 4 (1�12) 0.47
Treatment interruption Total cycle 260 280 0.02
Delayed cycle 90 (34.6%) 50 (17.8%)
Median delayed week 1 (1�4) 1 (1�4)
Median DI� 5-FU 857 (545�1,000) 913 (640�1,000) 0.02
[mg/m2/week (range)] Docetaxel or paclitaxel 21.4 (12.9�25) 53.2 (37.3�58.3)
Relative DI of taxanes Docetaxel or paclitaxel 0.86 0.91 0.03
Table 2. Treatment summary
*docetaxel, 5-fluorouracil, and leucovorin,�paclitaxel, 5-fluorouracil, and leucovorin,�dose intensity.
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3 Objective response
The overall response rate which was measured only in patients who
had measurable lesios, of total patients, was 31%. Following an
analysis which was performed based on an intent-to-treat principle,
the proportion of patients who showed more than a partial remission
was 26% (95% CI, 15�37%) in the DFL group and 38% (95% CI,
20�44%) in the PFL group (Table 3). There was no significant
difference in the response rate between the two groups (p=0.32).
These two groups were subdivided into two subgroups: the primary
treatment group and the secondary treatment group. According to this,
the response rate of the primary treatment group in both groups was
34% and 41% (p=0.57) and that of the secondary treatment group was
14% and 32% (p=0.06) in the corresponding order. These results
indicate that the response rate was significantly higher in the PFL
group, but this did not reach a statistical significance. The median time
to response was 2.0 months (range 1.5�6.0 months) in the DFL
group and 2.5 months (range 1.5�5.0 months) in the PFL group,
which showed that there was no significant difference between the
two groups. The period during which the response was persisted was
3 months (range 0.8�10.8 months) in the DFL group and 5.4 months
(range 2.6�8.2 months) in the PFL group. But this difference did not
reach a statistical significance (p=0.25) (Table 4).
4 Survival analysis 
Median follow-up period was 9.5 months at the time of survival
analysis. A comparison of the progression-free survival and the
overall survival period was made between the two groups, whose
results were represented in Table 4. A disease progression was seen in
54 patients of the DFL group and 53 patients of the PFL group. In
each group, 44 patients died. In total patients who were treated with
taxane, median period of progression-free survival was 4.5 months
(95% CI, 3.5�5.5 months). It was also evaluated in each treatment
group, which was 5.2 months (95% CI, 4.2�6.5 months) in the DFL
group and 3.3 months (95% CI, 1.3�5.5 months) in the PFL group
(Fig. 1A). A median period of progression-free survival was
examined in 50 patients of the PFL group, who had measurable
lesions, and it was 2.9 months (95% CI, 1.4�4.0 months). This was
not significantly different from a median period of progression-free
survival which was examined in total patients of the PFL group
(p=0.75) (Table 4). Besides, a median period of progression-free
survival was also examined only in patients who received the primary
treatment, which was 6.0 months (95% CI, 4.6�7.3 months) in the
DFL group and 4.8 months (95% CI, 2.8�6.8 months) in the PFL
group (p=0.35) (Fig. 2A). Furthermore, a median period of pro-
gression-free survival was also examined only in patients who
received the secondary treatment, which was 4.0 months (95% CI, 2.7
DFL* PFL�
N ITT� (%) PP§(%) N ITT� (%) PP§(%)
p-value
Total patients 66 50
Evaluable patients 59 46
CR‖ 2 3 3 2 4 4
PR¶ 15 23 26 17 34 37
SD** 23 35 39 11 22 24
PD�� 19 29 32 16 32 35
Response rate 26 29 38 41 0.32
Disease control rate 61 68 60 65 0.47
Table 3. Response evaluation 
*docetaxel, 5-fluorouracil, and leucovorin, �paclitaxel, 5-fluorouracil, and leucovorin, �intent-to-treat analysis, §per-protocol analysis, ‖complete response, ¶partial response; **stable
disease, ��progressive disease.
All patients
DFL� (months) PFL� (months)
p-value
median (95% CI§) median (95% CI)
PFS‖ 4.5 (3.5�5.5) 5.2 (4.2�6.5) 3.3 (1.3�5.5) 0.37
PFS* 4.5 (3.5�5.5) 5.2 (4.2�6.5) 2.9 (1.4�4.0) 0.12
OS¶ 12.0 (9.1�14.9) 10.0 (7.2�12.5) 13.9 (10.9�19.2) 0.17
OS* 11.4 (8.3�14.5) 10.0 (7.2�12.5) 13.8 (8.0�19.6) 0.34
Time to response 2.0 (0.9�6.2) 2.0 (1.5�6.0) 2.5 (1.5�5.0) 0.31
Response duration 3.5 (0.8�10.8) 3.0 (0.8�10.8) 5.4 (2.6�8.2) 0.25
Table 4. Survival analysis
*this analysis was performed only for patients of measurable disease, �docetaxel, 5-fluorouracil, and leucovorin, �paclitaxel, 5-fluorouracil, and leucovorin, §confidence interval, ‖pro-
gression free survival, ¶overall survival.
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�5.3 months) in the DFL group and 3.0 months (95% CI, 2.0�4.0
months) in the PFL group. These differences did not also reach a
statistical significance (p=0.48) (Fig. 2C).
In total patients, the median value of overall survival was 12.0
months (95% CI, 9.1�14.9 months). In each treatment group, the
median survival period was 10.0 months (95% CI, 7.2�12.5 months)
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Cancer Res Treat. 2009;41(4):196-204
202 CANCER  RESEARCH  AND  TREATMENT
in the DFL group and 13.9 months (95% 10.9�19.2 months) in the
PFL group (Fig. 1B). The median survival period was also evaluated
only in patients of the PFL group, who had measurable lesions, and it
was 13.8 months (95% CI, 8.0�19.6 months). This was not signifi-
cantly different from the median survival period which was evaluated
in total patients of the PFL group (p=0.99) (Table 4). Besides, the
overall survival was also evaluated only in patients who received the
primary treatment, which was 11.7 months (95% CI, 8.7�14.2) in
the DFL group and 16.5 months (95% CI, 11.3�21.8) in the PFL
group (p=0.46) (Fig. 2B). Furthermore, the overall survival was also
evaluated only in patients who received the secondary treatment,
which was 8.0 months (95% CI, 3.5�12.4) and 13.8 months (95%
CI, 7.3�20.3) in the corresponding order (p=0.15) (Fig. 2D).
5 Toxicity
Of patients of the DFL group, one died of febrile neutropenia and
septic shock following the first cycle of treatment. In the PFL group,
however, there were no drug-related deaths. In both groups, the most
common toxicities of Grade 3�4 in severity include neutropenia. A
Grade 4 neutropenia occurred at an incidence of 56% in the DFL
group, which was significantly higher than 37% seen in the PFL
group (p=0.03) (Table 5). Febrile neutropenia occurred at an
incidence of 12% in the DFL group, which was higher than 3% seen
in thePFL group. But this difference did not reach a statistical
significance (p=0.07). All of these cases were recovered to a level of >
Grade 1 using the conservative treatment. There was no significant
difference in the incidence of Grade 3�4 neutropenia between the
primary and secondary treatment groups (p=0.59). 
Grade 3�4 non-hematologic toxicities occurred in a total of ten
patients, and this incidence was relatively lower than the hematologic
toxicities. Non-hematologic toxicities showed a variability depending
on the type of taxanes which were administered. In the DFL group,
the major drug-related toxicities include mucositis (5%) and diarrhea
(3%). In the PFL group, however, they include nausea/vomiting (8%)
and neurotoxicity (5%). 
D i s c u s s i o n
The current study is an ad hoc analysis of two independent studies
which were conducted in a single-institution setting in patients with
progressive stomach cancer. It was conducted in patients who had
similar inclusion criteria during the similar period. DFL treatment
included only patients who had measurable lesions, whose primary
endpoint was the response rate. The preventive use of G-CSF was
allowed. But PFL treatment had the primary endpoint of progression-
free survival. Based on this, the number of patients who would be
recruited was determined. Accordingly, ten patients with assessable
lesions were also included. The therapeutic use of G-CSF was solely
allowed. As mentioned herein, two Phase II studies had no identical
study design in a detailed matter. But there were no significant
differences in the clinical characteristics between the two groups. The
treatment dose and interval were completely identical in drugs other
than taxanes. The pharmacodynamic titer of two types of taxanes was
similar. Based on these findings, a retrospective comparison of two
treatment regimens would not be problematic. It is therefore assumed
DFL* (n=66) PFL� (n=60)
Grade 3 Grade 4 Grade 3 Grade 4
Hematological toxicity
Anemia 1 (2) - 2 (3) -
Leukopenia 27 (41) 5 (8) 10 (17) 2 (3)
Neutropenia 10 (15) 37 (56) 15 (25) 22(37)
Thrombocytopenia - 1 (2) 1 (2) 1 (2)
Non-hematological toxicity
Nausea/vomiting 1 (2) - 5 (8) 4 (7)
Mucositis 3 (5) - - -
Diarrhea 2 (3) - - -
Hyperbilirubinemia - - - -
Elevated ALP� - - - -
Elevated transaminase 1 (2) - - -
Elevated serum Cr§ - - - -
Alopecia 2 (3) - - -
Infection - 2 (3) - -
Fever 1 (2) - - -
Peripheral neuropathy 1 (2) - 3 (5) -
Table 5. Toxicity profile
*docetaxel, 5-fluorouracil, and leucovorin, �paclitaxel, 5-fluorouracil, and leucovorin, �alkaline phosphatase, §creatinine.
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that the current data should be understood based on the extended
limitations of retrospective studies.
To date, only a limited number of studies have compared the
efficacy of paclitaxel and docetaxel. The results were that the efficacy
of these drugs varied depending on inclusion criteria, the establish-
ment of attempted endpoints and the viewpoint of interpretation.
According to ECOG 1594 study which was conducted in patients
with lung cancer, following a combination therapy using cisplatin and
taxane, there were no significant differences in the response rate and
survival period between the two drugs. Neutropenia of Grade 3�4 in
severity and neurotoxicity occurred at a similar incidence (9,10). By
contrast, according to Phase III studies which have been conducted in
patients with breast cancer, as compared with paclitaxel, docetaxel
had an excellent profile of the response rate and the progression-free
survival. It has also been reported, however, that the incidence of side
effects was relatively higher following the administration of docetaxel.
Following a concomitant use with carboplatin in patients with ovarian
cancer, both drugs had a similar profile of the efficacy and survival.
The severity of docetaxel treatment has been reported to be
significantly higher (11,12). But the greatest limitation of randomized
trials that are conducted as the primary treatment in patients with
stomach cancer is that the role of taxane has not been established as a
standard anti-cancer treatment as compared with the above-mentioned
cancers stomach cancer. Up to present, regarding the anti-cancer
treatments for stomach cancer, as compared with 5-FU monotherapy,
the excellent treatment outcomes have not been reported following the
use of ECF in Europe including the UK, following the use of CF in
Asia and following the use of CF according to JCOG9205 in Japan.
According to this, according to 5-FU monotherapy or the results of
recent trials such as JCOG9912 and SPIRITS, the anti-cancer
treatments based on S-1 have been considered as a standard modality
with the validity (13,14). In recent years, DCF therapy has been
indicated as a possible new standard treatment modality. Due to a
higher incidence (69%) of side effects of Grade 3�4 in severity and
that (82%) of neutropenia, there are many obstacles that such drugs
can be used as such in a clinical setting (15). Besides, many debates
have been made regarding whether concomitant treatment regimens
including capecitabin, proposed on Phase III studies in Korea, could
be established as a standard modality. Accordingly in the current
study, it was difficult to recruit patients who had no past history of
anti-cancer treatment and to interpret the results. Accordingly, the
interpretation of study results does not mean that either docetaxel or
paclitaxel is excellent for the treatment of stomach cancer. Besides, it
also pose a question whether a concomitant medication with 5-FU
excluding cisplatin would produce an equivalent profile of the
efficacy to DCF. There are almost no studies that have compared the
efficacy of taxane in patients with stomach cancer. In a situation
where there are a series of the pre-clinical evidences that there is a
discrepancy in the pharmacodynamic characteristics between the two
drugs contradictory to what has been predicted, the current study
might be of significance in that it would provide the baseline data for
the conduct of interventional studies and clinical ones that predict the
efficacy/safety of drugs in patients with progressive stomach cancer
(6). Actually, we’re currently conducting the clinical trials to confirm
the cross-reactivity of taxanes in patients with stomach cancer and a
series of interventional studies to examine single nucleotide
polymporphism (SNP) of binding sites for β-tubulin or the difference
in the sensitivity of inactivation enzymes. 
In the current study, despite the limitations mentioned above, DFL
and PFL have been demonstrated to have the efficacy and safety for
their primary and secondary treatments. The response rate and
survival period that were seen in both groups are similar to those seen
in a previous single study and a phase II study which was conducted
by Park et al. (16). Because a statistical titer was lowered due to a
limited number of enrolled patients, a meticulous analysis of the
difference in the treatment outcomes between the two groups could
not propose the results. In the DFL group, however, the response rate,
the side effects and the overall survival rate were unfavorable as
compared with the PFL group. It was also shown, however, that a
progression-free survival was prolonged. By contrast, despite a shorter
progression-free survival, the overall survival was favorable in the
PFL group. The former indicates that the tumor evaluation was
delayed every second cycle due to the prevalence of dose lowering or
delayed treatment. Besides, the latter indicates that the PFL treatment
is more advantageous for the compliance or the maintenance of
systemic status and thereby provides more opportunities for salvage
anti-cancer therapy. Although not conducted in the current study, an
assessment of the quality of life or an analysis of the time point of the
onset of side effects would further reflect these characteristics.
Furthermore, a 3-day consecutive intravenous infusion of 5-FU, its
resulting prolongation of length of hospital stay and the role of a low-
dose leucovorin could also be questionable. In recent years, a biweekly
or weekly schedule of 5-FU treatment where a prompt infusion is
coupled with a sequential one have frequently been used to treat
patients with colorectal cancer or stomach cancer. Based on the recent
reports that a weekly administration of taxanes secured the dose
intensity and its efficacy was not inferior to that of previous treatment
regimens, it can therefore be inferred that the dose and schedule of the
current treatment regimen should be further discussed considering the
side effects and compliance (17). 
In the current study, there were clear differences in the frequency
and degree of toxicity between docetaxel and paclitaxel. In the DFL
group, although the preventive use of G-CSF was allowed according
to the results of previous clinical studies, 71% of patients complained
of Grade 3�4 neutropenia and febrile neutropenia. This might lead to
the delayed treatment and the decreased dose intensity. Of note, 60%
of patients of the PFL group also complained of Grade 3�4
neutropenia. This Fig was significantly greater than approximately 10
�30% which has been reported on other studies (4,18). This might be
partially explained by the following reasons: (1) A hematologic
examination was meticulously performed on a weekly basis. (2) The
age of patients who were enrolled in the PFL group was relatively
higher (＞65 years of age, 20%). (3)  Patients had a poor performance
of the daily lives (ECOG 2, ≥50%).
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However, most of the neutropenia occurring in the PFL group were
easily resolved by the administration of G-CSF. The proportion of
cases in which neutropenia led to the occurrence of febrile neutropenia
was 3%, which was relatively good as compared with 12% seen in the
docetaxel group.
C o n c l u s i o n
This study suggests a concomitant treatment regimens such as DFL
or PFL which were performed in patients with progressive stomach
cancer showed no significant differences in the treatment effect and
safety. Both treatment regimens showed the effectiveness which was
equivalent to the previous ones.
In the DFL group, neutropenia and its resulting delayed anti-cancer
treatment, decreased dose and the difference in non-hematologic
toxicity could also be mentioned as the major difference between the
two treatment regimens. In the current study, however, it could not be
determined whether there is a significant superiority between do-
cetaxel and paclitaxel in patients with progressive stomach cancer. To
do this, the standard treatment regimens should be established in
patients with progressive stomach cancer. Moreover, conclusions
should be drawn through a comparison based on randomized trials.
Before then, further studies should continually be conducted to
examine the detailed pharmacodynamic profile and resistance
mechanisms of docetaxel and paclitaxel. Besides, further pharmaco-
genmic studies are also warranted to provide a detailed explaination
about the effectiveness and toxicity of each drug.
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